论文部分内容阅读
目的:评价西咪匹韦治疗基因1型丙型肝炎的疗效和安全性。方法:检索EMBASE、PubMed、The Cochrane Central Register of Controlled Trials、clinicaltrials.gov、CNKI全文数据库、万方数据库中关于西咪匹韦治疗基因1型丙型肝炎的疗效和安全性的随机对照试验,检索起始日期为2000年1月1日,截止时间为2016年8月8日。采用RevMan5.3对纳入的研究进行Meta分析。结果:共7项研究符合纳入标准入选本Meta分析,共纳入2 301例患者。分析结果显示西咪匹韦快速病毒学应答(RVR)、持续早期病毒应答(SVR12)、持续病毒学应答(SVR24)等获得率均明显高于对照组(P<0.000 1),病毒复发率明显低于对照组(P<0.000 1);100 mg组西咪匹韦RVR,SVR12,SVR24,病毒复发率等指标明显优于对照组(P<0.001),而150 mg组除了SVR24与对照组对比,差异无统计学意义外(P>0.05),其余指标均优于对照组(P<0.001)。西咪匹韦组一般不良反应发生率与对照组相比,差异无统计学意义(P>0.05),与临床治疗相关的不良反应中除了对光敏感发生率高于对照组,其余不良反应如皮疹、瘙痒、中性粒细胞减少、贫血事件发生率均与对照组对比无统计学差异(P>0.05)。结论:西咪匹韦用于治疗基因1型丙肝具有较好疗效及安全性。100 mg西咪匹韦较150 mg西咪匹韦用于治疗基因1型丙肝疗效更佳。
Objective: To evaluate the efficacy and safety of cimetidir in the treatment of genotype 1 hepatitis C. METHODS: Randomized controlled trials of EMBASE, PubMed, The Cochrane Central Register of Controlled Trials, clinicaltrials.gov, CNKI full-text database and Wanfang database for the efficacy and safety of cimetidir in the treatment of genotype 1 hepatitis C were searched. The starting date is January 1, 2000 and the deadline is August 8, 2016. Meta-analysis of the included studies was performed using RevMan 5.3. Results: A total of 7 studies met the inclusion criteria for inclusion in the meta-analysis and included a total of 2,301 patients. The results showed that the acquisition rates of rapid virological response (RVR), continuous early viral response (SVR12) and sustained virologic response (SVR24) were significantly higher than those of the control group (P <0.000 1). The recurrence rate of the virus was significant (P <0.0001). The indexes of RVR, SVR12, SVR24 and virus recurrence in 100 mg group were significantly better than those in control group (P <0.001), while those in 150 mg group were significantly higher than those in control group , The difference was not statistically significant (P> 0.05), the remaining indicators were better than the control group (P <0.001). There was no significant difference in the incidence of adverse reactions between the cimetidine group and the control group (P> 0.05). Adverse reactions associated with clinical treatment were more common than those in the control group. The other side effects Rash, pruritus, neutropenia, anemia events were no significant difference compared with the control group (P> 0.05). Conclusion: Cemedimir has good efficacy and safety in the treatment of genotype 1 hepatitis C. 100 milligrams of cimetidine is more effective than 150 milligrams of cimetidir in the treatment of genotype 1 hepatitis C.